Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec 2;42(26):126260.
doi: 10.1016/j.vaccine.2024.126260. Epub 2024 Sep 11.

COVID-19 vaccine uptake in a predominantly minoritized cohort hospitalized during the early pandemic in New York City

Jennifer Y Chang  1 , Michelle Chang  2 , Simian Huang  3 , Joan Bosco  4 , Meredith McNairy  5 , Sade Tukuru  6 , Yi Hao Wu  7 , Jonathan Kunkel-Jure  8 , Jessica Weidler  9 , Tawni Goodman  10 , Carlie Dorr  11 , Renée Roberts  12 , Brett Gray  13 , Jason Zucker  14 , Magdalena E Sobieszczyk  15 , Delivette Castor  16
Affiliations

COVID-19 vaccine uptake in a predominantly minoritized cohort hospitalized during the early pandemic in New York City

Jennifer Y Chang et al. Vaccine. .

Abstract

Background: Minoritized communities in the United States have had higher COVID-19 mortality and lower vaccine uptake. The influence of previous SARS-CoV-2 infection, initial disease severity, and persistent symptoms on COVID-19 vaccine uptake in Black and Latinx communities has not been examined.

Objective: To investigate whether initial COVID-19 severity, persistent symptoms, and other correlates affected vaccine uptake in a predominantly minoritized cohort hospitalized for COVID-19 during the early pandemic in New York City.

Design: In this historical cohort study, we abstracted electronic health record data on demographics, comorbidities, hospital oxygen requirements, symptoms at 3 and 6 months post-admission, COVID-19 vaccinations through November 2022, and influenza vaccinations during the 2018-2019 through 2021-2022 seasons. Unadjusted and adjusted odds ratios were estimated through logistic regression analyses of correlates of COVID-19 vaccination, on-time vaccination, and boosting.

Participants: Survivors among the first 1186 adult patients hospitalized for COVID-19 between March 1 and April 8, 2020 at a large quaternary care medical center in Northern Manhattan.

Main measures: Uptake of at least one COVID-19 vaccine dose, uptake of at least one booster, and on-time vaccination.

Key results: The 890 surviving individuals were predominantly Latinx (54%) and Non-Hispanic Black (15%). Most had one or more comorbidities (67%), and received at least one COVID-19 vaccine dose (78%). Among those vaccinated, 57% received at least one booster, and 31% delayed vaccination. 67% experienced persistent symptoms. Multiple logistic regression showed no association between vaccine uptake and disease severity or symptom persistence. However, older age and influenza vaccination during the COVID-19 era were associated with increased vaccination, booster uptake, and on-time vaccination.

Conclusions: Pinpointing drivers of vaccine uptake and hesitancy is critical to increasing and sustaining COVID-19 vaccination as the field transitions to annual boosters. The association between influenza vaccination and increased vaccine uptake suggests that bundling vaccines for adults may be an effective delivery strategy.

Keywords: COVID-19; Disease severity; Minoritized populations; Persistent symptoms; Vaccine uptake.

PubMed Disclaimer

Conflict of interest statement

Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Delivette Castor and Magdalena Sobieszczyk report financial support was provided by Gilead Sciences, Inc. Magdalena Sobieszczyk reports a relationship with Bill & Melinda Gates Foundation that includes: funding grants. Magdalena Sobieszczyk reports a relationship with Merck & Co Inc. that includes: funding grants. Magdalena Sobieszczyk reports a relationship with Sanofi that includes: funding grants. Magdalena Sobieszczyk reports a relationship with Pfizer Inc. that includes: funding grants. Jason Zucker reports a relationship with Centers for Disease Control and Prevention that includes: funding grants. If there are other authors, they declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. JZ has received a grant from the Centers for Disease Control and Prevention within the past 3 years. MES has received grants from the Gates Foundation, Merck, Sanofi, and Pfizer within the past 3 years for work outside the scope of this manuscript. Otherwise, the authors have no relevant financial or non-financial interests to disclose.

References

    1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard 2023. https://covid19.who.int/ (accessed July 4, 2023).
    1. Department of Health and Human Services. Fact Sheet: End of the COVID-19 Public Health Emergency 2023. https://www.hhs.gov/about/news/2023/05/09/fact-sheet-end-of-the-covid-19... (accessed August 11, 2024).
    1. Centers for Disease Control and Prevention. COVID-19 Vaccination Coverage and Vaccine Confidence Among Adults 2023. https://www.cdc.gov/vaccines/imz-managers/coverage/covidvaxview/interact... (accessed August 6, 2024).
    1. New York City Department of Health and Mental Hygiene. COVID-19: Data 2023. https://www.nyc.gov/site/doh/covid/covid-19-data-vaccines.page (accessed August 6, 2024).
    1. Yamana TK, Galanti M, Pei S, Di Fusco M, Angulo FJ, Moran MM, et al. The Impact of COVID-19 Vaccination in the US: Averted Burden of SARS-COV-2-Related Cases, Hospitalizations and Deaths. PLoS One 2023;18:e0275699. 10.1371/journal.pone.0275699. - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources